Article Text

Download PDFPDF
Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)

Abstract

Efficacy and safety of long term use of FK506 (2–4.5 mg/day) for a maximum of two years were evaluated in 12 patients with generalised myasthenia gravis (MG). At the end of the study, eight patients (67%) showed improvement in either MG score or Activities in Daily Living score, and prednisolone dosage could be reduced in seven patients (58%), with a mean reduction ratio of 37%. Long term use of FK506 for MG can be more effective than short term administration, with no serious side effects.

  • AChR, acetylcholine receptor
  • ADL, activities of daily living
  • MG, myasthenia gravis
  • clinical study
  • FK506
  • myasthenia gravis

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.